Table 3. All-cause mortality by age group, sex, and individual newer antipsychotic medication, N = 39,582a.
| Newer Antipsychotic Augmentation | Antidepressant Augmentation | |||||
|---|---|---|---|---|---|---|
| Subgroup | Deaths | Person Years | Deaths | Person Years | Adjusted Hazard Ratio (95% CI) | Adjusted Rate Difference (per 10,000 years of follow-up) (95% CI) |
| Age Group | ||||||
| 25 to 54 | 64 | 5,988 | 29 | 4,424 | 1.36 (0.86 to 2.13) | 23.6 (-9.2 to 74.1) |
| 55 to 64 | 41 | 1,613 | 19 | 1,303 | 1.61 (0.92 to 2.80) | 88.9 (-11.7 to 262.5) |
| Sex | ||||||
| Female | 77 | 5,716 | 32 | 4,533 | 1.72 (1.13 to 2.63) | 50.8 (9.2 to 115.1) |
| Male | 28 | 1,885 | 16 | 1,194 | 0.99 (0.52 to 1.87) | -1.3 (-64.3 to 116.6) |
| Generic APM | ||||||
| Quetiapine | 38 | 3,021 | 51 | 5,600 | 1.18 (0.77 to 1.82) | 16.4 (-20.9 to 74.7) |
| Risperidone | 25 | 1,568 | 50 | 5,669 | 1.66 (1.01 to 2.74) | 58.2 (0.9 to 153.5) |
| Aripiprazole | 11 | 1,183 | 31 | 3,678 | 0.88 (0.42 to 1.86) | -10.1 (-48.9 to 72.5) |
| Olanzapine | 22 | 1,155 | 44 | 5,387 | 1.92 (1.10 to 3.33) | 75.1 (8.2 to 190.3) |
aAfter propensity score trimming and inverse probability of treatment weighting; 365 day maximum follow-up, as-treated